See inside every stock. Pro
WatchlistPro
S&P 5007,663▼ 1.21%Nasdaq26,009▼ 2.60%Dow Jones52,868▲ 0.02%Nasdaq 10028,959▼ 2.90%VIX19.03▲ 14.09%US Dollar101.62▼ 0.16%Gold spot4,093▼ 0.80%WTI100.82▲ 1.36%

First Trust NYSE Arca Biotechnology Index (FBT)

Healthcare ETF · First Trust · NYSE ARCA · 32 holdings
$272.68 ▲ +0.22 (0.08%)
At close · USD · Volume 55,300
Returns and riskCostIncomeDividend historyHoldingsQuestions
52-week range
$186.20 – $275.23
Day's range
$270.06 – $273.24
1-year total return
+45.2%

FBT price chart

Daily, split-corrected, distributions markedEnd-of-day prices

FBT fund facts

FundFirst Trust NYSE Arca Biotechnology Index Fund
TickerFBT · NYSE ARCA
Issuer (by our rules)First Trust
Category (by our rules)Healthcare
Expense ratio0.55%
Holdings32
Net assets (fund, SEC)$2.8B
Yield (last 12 months)No distributions
DistributionsQuarterly
52-week range$186.20 – $275.23
Average volume (3 months)65,790
First price in our data23 Jun 2006
Issuer and category are assigned by StocksXray rules from the fund name. Expense ratio and net assets come from SEC filings; where a fund does not file them (for example grantor trusts) the field stays empty.

Returns and risk

1 month
−0.4%
3 months
+11.2%
6 months
+30.9%
Year to date
+32.0%
1 year
+45.2%
3 years a year
+25.7%
5 years a year
+11.2%
10 years a year
+11.9%
Volatility (1 year)
21.9%
Largest drop, last year
−14.3%
Largest drop in our data
−40.5%
Total return includes distributions, from end-of-day prices adjusted for splits and distributions, to 22 Oct 2026. Periods of 3 years and longer are annualised and shown only when the fund's history is long enough. Volatility is the standard deviation of daily returns over the last year, annualised. Past performance does not guarantee future results.

Cost: expense ratio

0.55% a year

On $10,000 invested that is about $55 a year in fund costs, taken out of the fund's assets.

Source: the fund's prospectus, as filed with the SEC on 30 Apr 2026 (risk/return summary data). Brokerage commissions and the bid-ask spread are separate costs.

Income: distributions

FBT paid no distributions in the last 12 months. Its return comes from price change only.

Cash paid per current share (restated for share splits), before tax, from EODHD.

FBT top holdings

#HoldingWeight
1 CORCEPT THERAPEUTICS INC 5.60%
2 NEOGENOMICS INC 5.12%
3 VERACYTE INC 5.10%
4 BRUKER CORP 4.32%
5 ALKERMES PLC 4.24%
6 ILLUMINA INC ILMN 3.92%
7 KRYSTAL BIOTECH INC 3.87%
8 NATERA INC 3.79%
9 AXSOME THERAPEUTICS INC 3.71%
10 NEUROCRINE BIOSCIENCES INC 3.53%
The top 10 make up 43.2% of the fund, out of 32 holdings.
Positions as of 30 Jun 2026, from the fund's Form N-PORT filed with the SEC. Public N-PORT holdings are quarter-end positions published about 60 days later, so they can be months old and the fund may have changed since.

Similar Healthcare ETFs

FHLC Fidelity MSCI Health Care Inde...0.08% fee · +25.8% 1y IXJ iShares Global Healthcare0.40% fee · +20.7% 1y IHE iShares U.S. Pharmaceuticals0.38% fee · +42.3% 1y VHT Vanguard Health Care0.09% fee · +25.6% 1y PPH VanEck Pharmaceutical0.36% fee · +29.3% 1y IHF iShares U.S. Healthcare Provid...0.38% fee · +20.6% 1y All healthcare ETFs →
Funds of the same category, nearest in trading size. Similar does not mean equivalent: check holdings and costs.

FBT: frequently asked questions

What is FBT?

FBT is the First Trust NYSE Arca Biotechnology Index ETF, issued by First Trust, listed on NYSE ARCA. By our rules it is classed as "Healthcare". Its latest SEC filing lists 32 holdings.

What is the expense ratio of FBT?

FBT charges 0.55% a year, according to its prospectus filed with the SEC on 30 Apr 2026. On $10,000 that is about $55 a year in fund costs.

Does FBT pay dividends?

No. We found no distributions for FBT in the last 12 months.

What does FBT hold?

The largest holdings in the latest SEC filing are CORCEPT THERAPEUTICS INC (5.6%), NEOGENOMICS INC (5.1%), VERACYTE INC (5.1%). The top 10 together make up 43.2% of the fund.

How has FBT performed?

Total return including distributions to 22 Oct 2026: 1 year +45.2%, 3 years +25.7% a year, 5 years +11.2% a year. Past performance does not guarantee future results.

Where the numbers come from

Prices and distributions end-of-day data from EODHD; returns are our own calculations from it.
Expense ratio and holdings SEC filings (prospectus risk/return data and Form N-PORT).
Category, issuer and leverage assigned by StocksXray rules from the fund name.
X-Ray look-through our scores applied to the SEC holdings.
Read the methodology →

StocksXray is for education only and is not financial advice or a recommendation to buy or sell anything. Past performance does not guarantee future results; funds can lose value.